Hegele, Robert A.

Combined hyperlipidemia: familial but not (usually) monogenic

Brahm, A. J., & Hegele, R. A. (2016) · Current Opinion in Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 71

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 71

Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target

Huff, M. W., & Hegele, R. A. (2013) · Circulation Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 70

Dyslipidemia

Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Conservative management in hypertriglyceridemia-associated pancreatitis

Berberich, A. J., Ziada, A., Zou, G. Y., & Hegele, R. A. (2019) · Journal of Internal Medicine

Pancreatitis Pathology and TreatmentGallbladder and Bile Duct Disorders

Cited by 67

Insulin's centenary: the birth of an idea

Hegele, R. A., & Maltman, G. M. (2020) · The Lancet Diabetes & Endocrinology

Medical History and InnovationsHistory of Science and Medicine

Cited by 64

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 63

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

Sanchez, E., Wilkinson, T., Coughlan, G., Mirza, S., Baril, A., Ramirez, J., Binns, M. A., Black, S. E., Borrie, M., Dilliott, A. A., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 62

Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility

Hegele, R. A., Breslow, J. L., & Cloninger, C. R. (1987) · Genetic Epidemiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 60

Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association

Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 60

Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation

Whitman, S. C., Miller, D. B., Wolfe, B. M., Hegele, R. A., & Huff, M. W. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 59

Cholesterol and apolipoprotein B metabolism in Tangier disease

Schaefer, E. J., Brousseau, M. E., Diffenderfer, M. R., Cohn, J. S., Welty, F. K., O'Connor, J., Dolnikowski, G. G., Wang, J., Hegele, R. A., & Jones, P. J. (2001) · Atherosclerosis

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 52

Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein

Bojic, L. A., Sawyez, C. G., Telford, D. E., Edwards, J. Y., Hegele, R. A., & Huff, M. W. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 51

Novel therapeutics in hypertriglyceridemia

Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 44

Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence

Chyzhyk, V., Kozmic, S., Brown, A. S., Hudgins, L. C., Starc, T. J., Davila, A. D., Blevins, T. C., Diffenderfer, M. R., He, L., Geller, A. S., et al. (2019) · Journal of Clinical Lipidology

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 44

Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy

Farhan, S. M. K., Nixon, K. C. J., Everest, M., Edwards, T. N., Long, S., Segal, D., Knip, M. J., Arts, H. H., Chakrabarti, R., Wang, J., et al. (2017) · Human Molecular Genetics

Epilepsy research and treatmentGenetics and Neurodevelopmental Disorders

Cited by 43

Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia

Reijman, M. D., Schweizer, A., Peterson, A. L. H., Bruckert, E., Stratz, C., Defesche, J. C., Hegele, R. A., & Wiegman, A. (2022) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 37

Familial visceral myopathy associated with a mitochondrial myopathy

Lowsky, R., Davidson, G., Wolman, S., Jeejeebhoy, K. N., & Hegele, R. A. (1993) · Gut

Mitochondrial Function and PathologyGastrointestinal motility and disorders

Cited by 36

Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes

Hegele, R. A. (2016) · Journal of Lipid Research

Lipid metabolism and disordersLipid metabolism and biosynthesis

Cited by 31

Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?

Hegele, R. A. (2022) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 29

Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping

Walden, C. C., Huff, M. W., Leiter, L. A., Connelly, P. W., & Hegele, R. A. (1994) · The Journal of Clinical Endocrinology & Metabolism

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 26

Genetic testing in monogenic early-onset atrial fibrillation

Chalazan, B., Freeth, E., Mohajeri, A., Ramanathan, K., Bennett, M., Walia, J., Halperin, L., Roston, T., Lazarte, J., Hegele, R. A., et al. (2023) · European Journal of Human Genetics

Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Cited by 23

Abstract 17120: ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results

Watts, G. F., Gaudet, D., ALTAMIRANO, D., Hegele, R., Ballantyne, C. M., Nicholls, S., Chang, T., Alagarsamy, S., Fu, R., San Martin, J., et al. (2023) · Circulation

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 9

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

Lachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A. (2023) · ClinicoEconomics and Outcomes Research

Health Systems, Economic Evaluations, Quality of LifeLipoproteins and Cardiovascular Health

Cited by 7